Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in Spain

Journal of Crohn's and Colitis

Volumn 4, Issue 5, 2010, Pages 567-574

  Gisbert, J P ^a   Gomollon F ^b   Hinojosa, J ^c   Román, A López San ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL DE MANISES   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

5 ASA; ECCO clinical guidelines; Inflammatory bowel disease; Mesalazine; Questionnary; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL PRACTICE; COLON CANCER; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENTERITIS; GASTROENTEROLOGIST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL SPECIALIST; MONOTHERAPY; ORGANIZATION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPAIN; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROSS-SECTIONAL STUDIES; EUROPE; GASTROENTEROLOGY; GUIDELINE ADHERENCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; SPAIN;

EID: 77958150861     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.06.001     Document Type: Article

References (21)

1. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
2. Irvine E.J. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm. Bowel Dis. 2008, 14:554-565.
3. Casellas F., Arenas J.I., Baudet J.S., Fabregas S., Garcia N., Gelabert J., et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm. Bowel Dis. 2005, 11:488-496.
4. Spiegel B.M., Ho W., Esrailian E., Targan S., Higgins P.D., Siegel C.A., et al. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 2009, 7:168-174.e1.
5. Odes S., Vardi H., Friger M., Wolters F., Russel M.G., Riis L., et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006, 131:719-728.
6. Stange E.F., Travis S.P.L., Vermeire S., Reinisch W., Geboes K., Barakauskiene A., et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohńs and Colitis 2008, 2:1-23.
7. Travis S.P.L., Stange E.F., Lemann M., Øresland T., Bemelman W.A., Chowers Y., et al. European evidence-based Consensus on the mnagement of ulcerative colitis: Current management. Journal of Crohńs and Colitis 2008, 2:24-62.
8. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997, 40:775-781.
9. Cohed R.D., Woseth D.M., Thisted R.A., Hanauer S.B. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol. 2000, 95:1263-1276.
10. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
11. Bergman R., Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006, 23:841-855.
12. López Sanromán A., Bermejo F. Review article: how to control and improve adherent to therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2006, 24:45-49.
13. Kane S., Huo D., Aikens J., Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med. 2003, 114:39-43.
14. Shale M.J., Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003, 18:191-198.
15. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol. 2001, 96:2929-2933.
16. Bassi A., Dodd S., Williamson P., Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004, 53:1471-1478.
17. Dignass A.U., Bokemeyer B., Adamek H., Mross M., Vinter-Jensen L., Börner N., et al. Once daily mesalamine is more effective than twice daily in patients with quiescent ulcerative colitis. Clin. Gastroenterol. Hepatol. 2009, 7:762-769.
18. Misiewicz J., Lennard-Jones J., Connel A., Baron J.H., Avery Jones F. Controlled trial of sulphasalazine in maintenance thrapy for ulcerative colitis. Lancet 1965, 1:185-188.
19. Velayos F.S., Terdiman J.P., Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. 2005, 100:1345-1353.
20. Rubin D.T., Cruz-Correa M.R., Gasche C., Jass J.R., Lichtenstein G.R., Montgomery E.A., et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm. Bowel Dis. 2008, 14:265-274.
21. Gawande A. The checklists: if something so simple can transform intensive care, what else can it do?. New Yorker. 2007, 10:86-101.